This site is intended for US healthcare professionals
Astellas Answers

Were patients with glaucoma included in the GATHER trials?

Published

Some patients in the GATHER1 and GATHER2 trials of avacincaptad pegol (ACP) had a prior history of glaucoma in the study eye, but no subgroup safety or efficacy analyses were conducted in these patients.1

ACP was assessed in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in two pivotal studies: GATHER1, a Phase 2/3 clinical trial, and GATHER2, a Phase 3 trial.2,3  Some participants had a baseline medical history of glaucoma in the study eye, which included open-angle glaucoma, normal tension glaucoma, borderline glaucoma, angle-closure glaucoma, and exfoliation glaucoma. No analyses were conducted to evaluate differences in the safety or efficacy of ACP in this patient population.

Table 1. Medical history of glaucoma in study eye at baseline – GATHER11

Table 2. Medical history of glaucoma in study eye at baseline – GATHER21

  1. Data on File.

  2. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021;128(4):576-586. https://dx.doi.org/10.1016/j.ophtha.2020.08.027.

  3. Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402(10411):1449-1458. https://dx.doi.org/10.1016/s0140-6736(23)01583-0.

If you are not able to find the information through the Search function, please contact our Medical Communications and Engagement Department by using any of the channels below:

Connect with Field Medical

Connect with Field Medical

Medical Science Liaisons (MSLs) and Medical Value and Access (MV&A) team members are available to help answer your scientific and health economic questions.

 

Submit an Inquiry

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

Hours: M–F, 8 AM–4:30 PM (CT)

Report an Adverse Event or Product Complaint

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)